|
|
|
| home > ebr > autumn 2003 > medicinal cannabis production - the botanist's view |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| Cannabis has been used for medicinal purposes for thousands of years in Asian and Middle Eastern countries. The medicinal use of cannabis in Europe and North America has declined during the 20th Century largely due to the lack of standardised preparations (1). The tide has turned. In the near future Britain should become the first country to license a cannabis-based pharmaceutical (2). The principal active ingredients responsible for the efficacy of cannabis are phytocannabinoids, a family of over sixty 21-carbon terpenophenolic compounds that are unique to cannabis. Sativex®, the first UK cannabis-based medicine contains two from this family - Tetrahydrocannabinol (THC) and Cannabidiol (CBD). THC is the principal psychoactive ingredient in recreational cannabis. CBD is not psychoactive but both cannabinoids have profound medicinal properties. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
BIO-Europe® 2012
12-14 November 2012, Congress Center Hamburg, Hamburg, Germany
Building value through partnerships
BIO-Europe® is the
preeminent partnering conference for the life sciences. BIO-Europe brings
together international decision makers from the biotechnology, pharmaceutical
and financial sectors, offering networking opportunities, workshop and panel
participation, a high profile exhibition, and private, prescheduled one-to-one
meetings.
More info >> |
|
 |
News and Press Releases |
 |
High performance range of insulated shipping systems
Laminar Medica’s Chilltherm® Global range of high performance insulated shipping systems, from 4 to 1130 litres product volume, are designed to offer optimal thermal protection for pharmaceutical products when exposed to extreme climates from -20°C to +40°C.
More info >> |
|
|
